期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 15, 期 9, 页码 1093-1103出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2015.1068120
关键词
Alzheimer disease; Alzheimer's disease assessment scale-activities of daily living; Alzheimer's disease assessment scale-cognitive subscale; capsule administration; patch administration; rivastigmine; weighted mean difference
资金
- department of Neurology in Liaocheng People's Hospital
- department of Psychiatry in Liaocheng People's Hospital
- department of endocrinology in Liaocheng People's Hospital
- Information Centre in Liaocheng People's Hospital
Aim: To evaluate the long-term effectiveness of rivastigmine patch or capsule on mild to severe Alzheimer's disease (AD). Method: We performed a meta-analysis of 17 studies regarding the treatment effectiveness of rivastigmine patch or capsule on mild-to-severe AD. Results: Significant difference exists between treatment with rivastigmine patch or capsule and placebo groups (p-value < 0.001). In the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score evaluation, a negative weighted mean difference (WMD) was observed in overall and mild-moderate groups after rivastigmine treatment. And in ADAS-ADL score evaluation, a positive WMD was observed in overall groups after rivastigmine treatment. Moreover, WMD value is lower in patch administration subgroup compared to that of capsule administration subgroup. Conclusion: Rivastigmine treatment shows a positive result of improving the condition of patients with mild-to-severe AD. Patch administration shows a stronger effect on decreasing ADAS-Cog score compared to capsule administration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据